A Phase 1b Study of WU-NK-101 in Combination With Cetuximab for Advanced and/or Metastatic Colorectal Cancer (CRC) and Advanced and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Latest Information Update: 18 Apr 2025
At a glance
- Drugs Cetuximab (Primary) ; WU NK 101 (Primary)
- Indications Carcinoma; Colorectal cancer; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors WUGEN
- 15 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2024 Planned primary completion date changed from 28 Feb 2025 to 30 Sep 2025.
- 15 Jun 2024 Status changed from not yet recruiting to recruiting.